Chou et al. 62 reported that hypermethylation of the FBXO32 promoter is more commonly observed in advanced‐stage ovarian tumours, and patients showing FBXO32 methylation exhibit significantly shorter PFS. The gene discussed is FBXO32; the disease is ovarian neoplasm.